NPS Pharmaceuticals, Inc. (NASDAQ: NPSP)

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is focused on the development of specialty therapeutics for gastrointestinal and endocrine disorders. Currently, the company is progressing two late-stage programs: GATTEX™ (teduglutide), which is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome; and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection), which is in Phase 2 clinical development as a hormone therapy for hypoparathyroidism. For further information, visit the Company’s web site at www.npsp.com.